Cortechs.ai | NeuroQuant®: Contrast agents not required

NeuroQuant®: Contrast agents not required

Factors which degrade the technical quality of MR images or pathologic processes, which significantly affect neuroanatomic structure, may decrease the accuracy of NeuroQuant® output. One of these factors is the use of contrast agents.

Contrast agents are typically used to study vasculature, something that is not needed for volumetric MR imaging. NeuroQuant requires a non-contrasted, 3D T1 sagittal sequence to segment and measure brain structure volumes.

NeuroQuant does not support a contrast enhanced study. The presence of contrast will cause misregistration of cortical and subcortical structures. The segmentation, volumetrics and normative comparisons will be inaccurate when contrast agents are used.

Some examples of NeuroQuant processed with and without contrast agents are shown below.

Cortechs.ai | NeuroQuant®: Contrast agents not required

More information about using NeuroQuant can be found here.

More Resources

06/04/2026

SNMMI 2026: Advancing the Future of Quantitative PET in Dementia Imaging

At SNMMI 2026, Cortechs.ai showcased NeuroQuant® PET and the growing role of quantitative PET imaging in dementia care.

06/02/2026

Cortechs.ai Collaborates with Microsoft to Bring AI-Powered Imaging Insights Directly into Radiology Workflows

Cortechs.ai and Microsoft are partnering to help bring advanced AI-powered quantitative imaging directly into radiology workflows.

05/26/2026

Cortechs.ai Partners with ARJ Medical to Advance AI-Driven Neuro and Prostate Imaging in the Middle East

Cortechs.ai and ARJ Medical have partnered to expand access to AI-powered neuro and prostate imaging solutions across the Middle East.

05/26/2026

ASNR 2026 Highlights the Growing Role of Quantitative Imaging in Neurology

ASNR 2026 brought together leaders across neuroradiology, imaging AI, and neurological care to explore the future of quantitative imaging.

05/11/2026

Better Models, Better Care: Inside Our Latest Brain Tumor Update

Explore how NeuroQuant® Brain Tumor v2.1 advances AI-powered brain tumor segmentation and clinical workflows.

05/05/2026

The American Academy of Neurology: Shaping the Future of Neurologic Care 

AI-driven clinical quantification is becoming standard in neurologic care
Scroll to Top